Oblique Therapeutics have developed a family of antagonistic antibodies targeting the ion channel TRPA1 for treatment of pain, cough, and itch.
Oblique has identified several potent aTRX mAbs that bind and neutralize Trx1 activity. These antibodies are being evaluated for immune modulation and anti-tumor activity
OT-1096 is a first-in-class small molecule with potential to treat advanced metastatic diseases including triple-negative breast cancer.
Oblique Therapeutics has developed high affinity, stimuli-selective antibodies against the pain receptor TRPV1 in order to maximize pain relief and circumvent side effects. This asset is currently partnered with a top-20 pharma company.
Oblique has developed a pipeline of mutant selective aKRAS mAbs where the most advanced program targeting the KRAS G13D mutation has shown efficacy in a colorectal cancer xenograft model.
